Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Identification of Potential Biomarkers in Peripheral Blood Supernatants of South African Patients with Syphilitic and Herpetic Uveitis.

Andreae CD, Smit DP, Makhoba NS, Kidd M, Walzl G, Chegou NN.

Ocul Immunol Inflamm. 2019 Nov 7:1-9. doi: 10.1080/09273948.2019.1674341. [Epub ahead of print]

PMID:
31697216
2.

Time-Dependent Changes in Urinary Metabolome Before and After Intensive Phase Tuberculosis Therapy: A Pharmacometabolomics Study.

Combrink M, du Preez I, Ronacher K, Walzl G, Loots DT.

OMICS. 2019 Nov;23(11):560-572. doi: 10.1089/omi.2019.0140. Epub 2019 Oct 15.

PMID:
31613685
3.

Potential of Host Serum Protein Biomarkers in the Diagnosis of Tuberculous Meningitis in Children.

Manyelo CM, Solomons RS, Snyders CI, Mutavhatsindi H, Manngo PM, Stanley K, Walzl G, Chegou NN.

Front Pediatr. 2019 Sep 25;7:376. doi: 10.3389/fped.2019.00376. eCollection 2019.

4.

Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis.

Drain PK, Gardiner J, Hannah H, Broger T, Dheda K, Fielding K, Walzl G, Kaforou M, Kranzer K, Joosten SA, Gilpin C, Weyer K, Denkinger CM, Schumacher SG.

J Infect Dis. 2019 Oct 8;220(Supplement_3):S108-S115. doi: 10.1093/infdis/jiz356.

PMID:
31593598
5.

Distinct serum biosignatures are associated with different tuberculosis treatment outcomes.

Ronacher K, Chegou NN, Kleynhans L, Djoba Siawaya JF, du Plessis N, Loxton AG, Maasdorp E, Tromp G, Kidd M, Stanley K, Kriel M, Menezes A, Gutschmidt A, van der Spuy GD, Warren RM, Dietze R, Okwera A, Thiel B, Belisle JT, Cliff JM, Boom WH, Johnson JL, van Helden PD, Dockrell HM, Walzl G.

Tuberculosis (Edinb). 2019 Sep;118:101859. doi: 10.1016/j.tube.2019.101859. Epub 2019 Aug 12.

6.

Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals.

Manngo PM, Gutschmidt A, Snyders CI, Mutavhatsindi H, Manyelo CM, Makhoba NS, Ahlers P, Hiemstra A, Stanley K, McAnda S, Kidd M, Malherbe ST, Walzl G, Chegou NN.

J Infect. 2019 Sep;79(3):228-235. doi: 10.1016/j.jinf.2019.07.007. Epub 2019 Jul 15.

7.

Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Jul 18;16(7):e1002880. doi: 10.1371/journal.pmed.1002880. eCollection 2019 Jul.

8.

Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy.

Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, Duffy FJ, Fisher M, Filander E, van Rooyen M, Bilek N, Mabwe S, McKinnon LR, Chegou N, Loxton A, Walzl G, Tromp G, Padayatchi N, Govender D, Hatherill M, Karim SA, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team.

Front Microbiol. 2019 Jun 26;10:1441. doi: 10.3389/fmicb.2019.01441. eCollection 2019.

9.

Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell-killing capability.

Ribechini E, Eckert I, Beilhack A, Du Plessis N, Walzl G, Schleicher U, Ritter U, Lutz MB.

JCI Insight. 2019 Jun 4;5. pii: 128664. doi: 10.1172/jci.insight.128664.

10.

Application of Cerebrospinal Fluid Host Protein Biosignatures in the Diagnosis of Tuberculous Meningitis in Children from a High Burden Setting.

Manyelo CM, Solomons RS, Snyders CI, Manngo PM, Mutavhatsindi H, Kriel B, Stanley K, Walzl G, Chegou NN.

Mediators Inflamm. 2019 Apr 16;2019:7582948. doi: 10.1155/2019/7582948. eCollection 2019.

11.

Oxidized low-density lipoprotein (oxLDL) supports Mycobacterium tuberculosis survival in macrophages by inducing lysosomal dysfunction.

Vrieling F, Wilson L, Rensen PCN, Walzl G, Ottenhoff THM, Joosten SA.

PLoS Pathog. 2019 Apr 18;15(4):e1007724. doi: 10.1371/journal.ppat.1007724. eCollection 2019 Apr.

12.

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Apr 16;16(4):e1002781. doi: 10.1371/journal.pmed.1002781. eCollection 2019 Apr. Erratum in: PLoS Med. 2019 Jul 18;16(7):e1002880.

13.

Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome.

Duffy FJ, Weiner J 3rd, Hansen S, Tabb DL, Suliman S, Thompson E, Maertzdorf J, Shankar S, Tromp G, Parida S, Dover D, Axthelm MK, Sutherland JS, Dockrell HM, Ottenhoff THM, Scriba TJ, Picker LJ, Walzl G, Kaufmann SHE, Zak DE; GC6-74 Consortium.

Front Immunol. 2019 Mar 22;10:527. doi: 10.3389/fimmu.2019.00527. eCollection 2019.

14.

Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study.

Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, Cioboata R, Llontop JC, Kleynhans L, Lopez S, Santoso P, Marius C, Villaizan K, Ruslami R, Walzl G, Panduru NM, Dockrell HM, Hill PC, Mc Allister S, Pearson F, Moore DAJ, Critchley JA, van Crevel R; TANDEM Consortium.

Clin Infect Dis. 2019 Apr 8. pii: ciz284. doi: 10.1093/cid/ciz284. [Epub ahead of print]

PMID:
30958536
15.

The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda.

Naidoo CC, Nyawo GR, Wu BG, Walzl G, Warren RM, Segal LN, Theron G.

Lancet Respir Med. 2019 Oct;7(10):892-906. doi: 10.1016/S2213-2600(18)30501-0. Epub 2019 Mar 22. Review.

PMID:
30910543
16.

Point of care HbA1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countries.

Huangfu P, Laurence YV, Alisjahbana B, Ugarte-Gil C, Riza AL, Walzl G, Ruslami R, Moore DAJ, Ioana M, McAllister S, Ronacher K, Koesoemadinata RC, Grint D, Kerry S, Coronel J, Malherbe ST, Griffiths U, Dockrell HM, Hill PC, van Crevel R, Pearson F, Critchley JA.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):283-292. doi: 10.5588/ijtld.18.0359.

PMID:
30871659
17.

Correction to "Elucidation of a Novel Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy".

Fitzgerald BL, Islam MN, Graham B, Mahapatra S, Webb K, Boom WH, Malherbe ST, Joloba ML, Johnson JL, Winter J, Walzl G, Belisle JT.

ACS Infect Dis. 2019 Jun 14;5(6):1042-1043. doi: 10.1021/acsinfecdis.9b00068. Epub 2019 Mar 13. No abstract available.

18.

The level of the endoplasmic reticulum stress chaperone protein, binding immunoglobulin protein (BiP), decreases following successful tuberculosis treatment.

Motaung B, Walzl G, Loxton AG.

Int J Infect Dis. 2019 Apr;81:198-202. doi: 10.1016/j.ijid.2019.01.030. Epub 2019 Jan 23.

19.

Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube.

Nemes E, Abrahams D, Scriba TJ, Ratangee F, Keyser A, Makhethe L, Erasmus M, Mabwe S, Bilek N, Rozot V, Geldenhuys H, Hatherill M, Lempicki MD, Holm LL, Bogardus L, Ginsberg AM, Blauenfeldt T, Smith B, Ellis RD, Loxton AG, Walzl G, Andersen P, Ruhwald M.

Clin Infect Dis. 2019 Oct 30;69(10):1724-1730. doi: 10.1093/cid/ciz034.

20.

Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response.

Warsinske HC, Rao AM, Moreira FMF, Santos PCP, Liu AB, Scott M, Malherbe ST, Ronacher K, Walzl G, Winter J, Sweeney TE, Croda J, Andrews JR, Khatri P.

JAMA Netw Open. 2018 Oct 5;1(6):e183779. doi: 10.1001/jamanetworkopen.2018.3779.

21.

Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy.

Fitzgerald BL, Islam MN, Graham B, Mahapatra S, Webb K, Boom WH, Malherbe ST, Joloba ML, Johnson JL, Winter J, Walzl G, Belisle JT.

ACS Infect Dis. 2019 Mar 8;5(3):353-364. doi: 10.1021/acsinfecdis.8b00241. Epub 2019 Jan 10. Erratum in: ACS Infect Dis. 2019 Jun 14;5(6):1042-1043.

22.

Metabolite changes in blood predict the onset of tuberculosis.

Weiner J 3rd, Maertzdorf J, Sutherland JS, Duffy FJ, Thompson E, Suliman S, McEwen G, Thiel B, Parida SK, Zyla J, Hanekom WA, Mohney RP, Boom WH, Mayanja-Kizza H, Howe R, Dockrell HM, Ottenhoff THM, Scriba TJ, Zak DE, Walzl G, Kaufmann SHE; GC6-74 consortium.

Nat Commun. 2018 Dec 6;9(1):5208. doi: 10.1038/s41467-018-07635-7.

23.

Diabetes screen during tuberculosis contact investigations highlights opportunity for new diabetes diagnosis and reveals metabolic differences between ethnic groups.

Restrepo BI, Kleynhans L, Salinas AB, Abdelbary B, Tshivhula H, Aguillón-Durán GP, Kunsevi-Kilola C, Salinas G, Stanley K, Malherbe ST, Maasdorp E, Garcia-Viveros M, Louw I, Garcia-Oropesa EM, Lopez-Alvarenga JC, Prins JB, Walzl G, Schlesinger LS, Ronacher K.

Tuberculosis (Edinb). 2018 Dec;113:10-18. doi: 10.1016/j.tube.2018.08.007. Epub 2018 Aug 18.

24.

Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa.

Grint D, Alisjhabana B, Ugarte-Gil C, Riza AL, Walzl G, Pearson F, Ruslami R, Moore DAJ, Ioana M, McAllister S, Ronacher K, Koeseomadinata RC, Kerry-Barnard SR, Coronel J, Malherbe ST, Dockrell HM, Hill PC, Van Crevel R, Critchley JA; TANDEM consortium.

Bull World Health Organ. 2018 Nov 1;96(11):738-749. doi: 10.2471/BLT.17.206227. Epub 2018 Aug 27.

25.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

26.

Human Monocytic Suppressive Cells Promote Replication of Mycobacterium tuberculosis and Alter Stability of in vitro Generated Granulomas.

Agrawal N, Streata I, Pei G, Weiner J, Kotze L, Bandermann S, Lozza L, Walzl G, du Plessis N, Ioana M, Kaufmann SHE, Dorhoi A.

Front Immunol. 2018 Oct 23;9:2417. doi: 10.3389/fimmu.2018.02417. eCollection 2018.

27.

Author Correction: A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, Rozot V, Nemes E, Malherbe ST, Ronacher K, Walzl G, Hanekom W, Davis MM, Winter J, Chen X, Scriba TJ, Khatri P, Chien YH.

Nature. 2018 Dec;564(7734):E5. doi: 10.1038/s41586-018-0635-8.

28.

Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):564-571. doi: 10.1164/rccm.201806-1053PP. No abstract available.

29.

Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.

du Plessis N, Kotze LA, Leukes V, Walzl G.

Front Cell Infect Microbiol. 2018 Sep 21;8:332. doi: 10.3389/fcimb.2018.00332. eCollection 2018. Review.

30.

PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis.

Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, Wilkinson RJ, Burgers WA, Hanekom WA.

Front Immunol. 2018 Aug 31;9:1995. doi: 10.3389/fimmu.2018.01995. eCollection 2018.

31.

A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, Rozot V, Nemes E, Malherbe ST, Ronacher K, Walzl G, Hanekom W, Davis MM, Winter J, Chen X, Scriba TJ, Khatri P, Chien YH.

Nature. 2018 Aug;560(7720):644-648. doi: 10.1038/s41586-018-0439-x. Epub 2018 Aug 22. Erratum in: Nature. 2018 Dec;564(7734):E5.

32.

Disease characteristics and treatment of patients with diabetes mellitus attending government health services in Indonesia, Peru, Romania and South Africa.

Soetedjo NNM, McAllister SM, Ugarte-Gil C, Firanescu AG, Ronacher K, Alisjahbana B, Costache AL, Zubiate C, Malherbe ST, Koesoemadinata RC, Laurence YV, Pearson F, Kerry-Barnard S, Ruslami R, Moore DAJ, Ioana M, Kleynhans L, Permana H, Hill PC, Mota M, Walzl G, Dockrell HM, Critchley JA, van Crevel R; TANDEM Consortium.

Trop Med Int Health. 2018 Oct;23(10):1118-1128. doi: 10.1111/tmi.13137. Epub 2018 Sep 10.

33.

Diagnostic Challenge of Tuberculosis Heterogeneity.

Nemes E, Meermeier EW, Scriba TJ, Walzl G, Malherbe ST, Lewinsohn DM.

Semin Respir Crit Care Med. 2018 Jun;39(3):286-296. doi: 10.1055/s-0038-1660471. Epub 2018 Aug 2. Review.

PMID:
30071544
34.

A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images.

Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Barry CE 3rd, Griffith-Richards S, Ellman A, Ronacher K, Winter J, Walzl G, Warwick JM; Catalysis Biomarker Consortium.

EJNMMI Res. 2018 Jun 25;8(1):55. doi: 10.1186/s13550-018-0411-7.

35.

The potential of imaging tools as correlates of infection and disease for new TB vaccine development.

Malherbe ST, Kleynhans L, Walzl G.

Semin Immunol. 2018 Oct;39:73-80. doi: 10.1016/j.smim.2018.06.001. Epub 2018 Jun 18. Review.

PMID:
29914653
36.

Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile.

Vrieling F, Ronacher K, Kleynhans L, van den Akker E, Walzl G, Ottenhoff THM, Joosten SA.

EBioMedicine. 2018 Jun;32:192-200. doi: 10.1016/j.ebiom.2018.05.011. Epub 2018 May 17.

37.

A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts.

Duffy FJ, Thompson E, Downing K, Suliman S, Mayanja-Kizza H, Boom WH, Thiel B, Weiner Iii J, Kaufmann SHE, Dover D, Tabb DL, Dockrell HM, Ottenhoff THM, Tromp G, Scriba TJ, Zak DE, Walzl G; GC6-74 Consortium.

Front Immunol. 2018 Apr 13;9:661. doi: 10.3389/fimmu.2018.00661. eCollection 2018.

38.

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; GC6-74 and ACS cohort study groups.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340OC. [Epub ahead of print]

39.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
40.

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.

Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e199-e210. doi: 10.1016/S1473-3099(18)30111-7. Epub 2018 Mar 23. Review.

PMID:
29580818
41.

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M.

Tuberculosis (Edinb). 2018 Mar;109:61-68. doi: 10.1016/j.tube.2017.11.009. Epub 2017 Nov 22.

42.

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.

Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1.

43.

Decreased neutrophil-associated miRNA and increased B-cell associated miRNA expression during tuberculosis.

van Rensburg IC, du Toit L, Walzl G, du Plessis N, Loxton AG.

Gene. 2018 May 20;655:35-41. doi: 10.1016/j.gene.2018.02.052. Epub 2018 Feb 23.

PMID:
29477867
44.

Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.

Chegou NN, Sutherland JS, Namuganga AR, Corstjens PL, Geluk A, Gebremichael G, Mendy J, Malherbe S, Stanley K, van der Spuy GD, Kriel M, Loxton AG, Kriel B, Simukonda F, Bekele Y, Sheehama JA, Nelongo J, van der Vyver M, Gebrexabher A, Hailu H, Esterhuyse MM, Rosenkrands I, Aagard C, Kidd M, Kassa D, Mihret A, Howe R, Cliff JM, Crampin AC, Mayanja-Kizza H, Kaufmann SHE, Dockrell HM, Ottenhoff THM, Walzl G; AE-TBC consortium.

Sci Rep. 2018 Feb 8;8(1):2675. doi: 10.1038/s41598-018-20855-7.

45.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Dec 7;23(12):1499. doi: 10.1038/nm1217-1499a.

46.

Predicting tuberculosis treatment outcome using metabolomics.

Luies L, Reenen MV, Ronacher K, Walzl G, Loots DT.

Biomark Med. 2017 Dec;11(12):1057-1067. doi: 10.2217/bmm-2017-0133. Epub 2017 Nov 27.

PMID:
29172670
47.

Host blood RNA signatures predict the outcome of tuberculosis treatment.

Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE; Catalysis TB–Biomarker Consortium.

Tuberculosis (Edinb). 2017 Dec;107:48-58. doi: 10.1016/j.tube.2017.08.004. Epub 2017 Aug 12.

48.

Effect of HIV on the Frequency and Number of Mycobacterium tuberculosis-Specific CD4+ T Cells in Blood and Airways During Latent M. tuberculosis Infection.

Bunjun R, Riou C, Soares AP, Thawer N, Müller TL, Kiravu A, Ginbot Z, Oni T, Goliath R, Kalsdorf B, von Groote-Bidlingmaier F, Hanekom W, Walzl G, Wilkinson RJ, Burgers WA.

J Infect Dis. 2017 Dec 19;216(12):1550-1560. doi: 10.1093/infdis/jix529.

49.

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.

Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, van der Zalm M, Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team.

Clin Infect Dis. 2018 Feb 1;66(4):554-563. doi: 10.1093/cid/cix834.

50.

Suitability of saliva for Tuberculosis diagnosis: comparing with serum.

Namuganga AR, Chegou NN, Mubiri P, Walzl G, Mayanja-Kizza H.

BMC Infect Dis. 2017 Aug 31;17(1):600. doi: 10.1186/s12879-017-2687-z.

Supplemental Content

Support Center